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Experimental allergic encephalomyelitis (EAE) serves as a model for multiple sclerosis and is 
considered to be a CD4
 
 
 
 Th1 cell–mediated autoimmune disease. To investigate the role of 
platelet-activating factor (PAF) in this disease, PAF receptor (PAFR) KO (PAFR-KO) and 
wild-type (WT) mice, on a C57BL/6 genetic background, were immunized with myelin 
oligodendrocyte glycoprotein 35–55. The levels of PAF production and PAFR mRNA expression 
in the spinal cord (SC) correlated with the EAE symptoms. PAFR-KO mice showed lower 
incidence and less severe symptoms in the chronic phase of EAE than WT mice. However, no 
difference was observed in T cell proliferation, Th1-cytokine production, or titer of IgG2a 
between both genotypes. Before onset, as revealed by microarray analysis, mRNAs of 
inflammatory mediators and their receptors—including IL-6 and CC chemokine receptor 2—
were down-regulated in the SC of PAFR-KO mice compared with WT mice. Moreover, in the 
chronic phase, the severity of inflammation and demyelination in the SC was substantially 
reduced in PAFR-KO mice. PAFR-KO macrophages reduced phagocytic activity and 
subsequent production of TNF-
 
 
 
. These results suggest that PAF plays a dual role in EAE 
pathology in the induction and chronic phases through the T cell–independent pathways.
 
Multiple sclerosis (MS) is considered to be
a CD4
 
 
 
 T cell–mediated disease that exhibits
inflammation and demyelination in the central
nervous system (CNS) (1). Although genetic
and environmental factors are implicated in
the pathogenesis of MS (2), the mechanism for
MS remains obscure. Experimental allergic
encephalomyelitis (EAE) is an indispensable
animal model for a better understanding of MS
pathogenesis (3). EAE, as well as MS, seem to
be autoimmune diseases because of the presence
of CD4
 
 
 
 T cells that are responsive to autoanti-
gens (myelin basic protein, MBP; proteolipid
protein, PLP; myelin oligodendrocyte glyco-
protein, MOG) and the participation of Th1-
type inflammatory molecules (3). Meanwhile,
it has been suggested that allergic responses
may also play a role in the pathogenesis of
EAE (4–6).
Platelet-activating factor (PAF, 1-
 
O
 
-alkyl-
2-acetyl-
 
sn
 
-glycero-3-phosphocholine) is a lipid
mediator that has biological effects on a variety
of cells and organs (7). PAF is produced by
various kinds of cells, including neutrophils,
eosinophils, monocytes/macrophages, and vas-
cular endothelial cells (8). Bioactivities of PAF
are elicited by binding to the PAF receptor
(PAFR), which belongs to the superfamily of
G protein–coupled seven-transmembrane recep-
tors (9). To elucidate the biological and patho-
physiological functions of PAF, we generated
PAFR-KO mice and demonstrated that the
PAFR deficiency protected mice from many
allergic and inflammatory disorders (7, 10–12).
Several lines of evidence suggest that PAF may
also play a role in autoimmune diseases, like MS/
EAE (5, 13, 14). For example, PAF levels were
elevated in the cerebrospinal fluid and plasma
of patients who had the relapsing-remitting
form of MS (13), and increased levels of PAFR
transcripts in MS lesions were revealed by
gene-microarray analysis (14). PAFR transcripts
were also up-regulated in the brain and spinal
cord (SC) from SJL mice with EAE (5). Al-
though these studies suggest that PAF contributes
to the pathology of MS/EAE through PAFR,
much less is known about how PAF affects the
pathology of MS or EAE. In the present study,
 
The online version of this article contains supplemental material.
 
CORRESPONDENCE
Takao Shimizu: 
tshimizu@m.u-tokyo.ac.jp
 
Abbreviations used: cPLA
 
2
 
, 
cytosolic phospholipase A
 
2; 
 
CNS, 
central nervous system; EAE, 
experimental allergic encephalo-
myelitis; ESI, electrospray ioniza-
tion; H&E, hematoxylin-eosin; 
LFB, luxol fast blue; lyso-PAF 
AT; lyso-PAF acetyltransferase; 
MCP, monocyte chemoattractant 
protein; MOG, myelin oligo-
dendrocyte glycoprotein; MS, 
multiple sclerosis; MS/MS, 
tandem mass spectrometry; PAF, 
platelet-activating factor; PAFR, 
PAF receptor; SC, spinal cord. 
ROLE OF PLATELET-ACTIVATING FACTOR IN EAE | Kihara et al.
 
854
 
we induced EAE in PAFR-KO mice and wild-type (PAFR-
WT) controls with MOG
 
35–55
 
 peptide, and disclosed that
PAF worsens EAE pathology in the induction and chronic
phases, probably through the T cell–independent pathways.
 
RESULTS
Changes in PAFR mRNA expression and PAF production 
in SC were correlated with progression of EAE pathology
 
To understand the roles of the PAF/PAFR system in EAE
pathology, we first examined the levels of PAFR mRNA
expression by quantitative real-time PCR and PAF produc-
tion by reversed-phase HPLC–electrospray ionization (ESI)–
tandem mass spectrometry (MS/MS). C57BL/6 mice were
immunized with MOG
 
35–55
 
 peptide (Fig. 1 A), and SCs were
removed from naive mice and EAE mice on days 11, 18, and
30. Expression levels of PAFR transcripts were correlated
with the disease progression (Fig. 1 B). Namely, the amounts
of PAFR transcripts in almost all SCs of naive mice and EAE
mice on day 11 were less than the detection limit. However,
PAFR transcripts were elevated dramatically on day 18 and
then declined on day 30 to levels that were still higher than
those on days 0 and 11. Fig. 1 C shows the PAF levels in
SCs of naive and EAE mice. PAF level was 4.3 
 
 
 
 0.8 pg/mg
tissue in naive mice, and tended to increase slightly in EAE
mice on day 11 (5.8 
 
 
 
 0.1 pg/mg tissue). PAF level on day
18 (19.3 
 
 
 
 0.6 pg/mg tissue) was increased significantly—
4.5 times as much as naive mice (P 
 
 
 
 0.001). Meanwhile,
PAF level on day 30 (11.3 
 
 
 
 0.3 pg/mg tissue) was de-
creased significantly to 
 
 
 
60% of that on day 18 (P 
 
 
 
 0.01),
yet remained higher than that in naive mice (P 
 
 
 
 0.05). We
found a significantly positive correlation between the clinical
score and the PAF production in SC (P 
 
 
 
 0.0001) (Fig. 1
D). These results suggest that the PAF/PAFR system is es-
sential for the pathogenesis of EAE.
 
PAFR-KO mice showed less severe symptoms and lower 
incidence of EAE
 
PAFR-WT and PAFR-KO mice were immunized with
MOG
 
35–55
 
 peptide and monitored for up to 42 d. There was a
significant difference in the course of the disease between
PAFR-WT and PAFR-KO mice (P 
 
 
 
 0.0001) (Fig. 2, A and
C). Furthermore, the body weight loss in PAFR-WT mice
was significantly more severe than that in PAFR-KO mice
(P 
 
 
 
 0.0001) (Fig. 2, B and D). Clinical parameters of EAE
are summarized in Table I. PAFR-KO mice showed a sig-
nificantly lower incidence of disease (69%) compared with
PAFR-WT mice (97%; P 
 
 
 
 0.01). The day of disease onset in
PAFR-KO mice was similar to that in PAFR-WT mice. The
mean maximal score of PAFR-KO mice was significantly
lower than that of PAFR-WT mice (P 
 
 
 
 0.05); the number
of PAFR-KO mice with a maximal score of 
 
 
 
2.5 was signifi-
cantly less than that of PAFR-WT mice (P 
 
 
 
 0.05).
 
PAFR deficiency suppressed sustained inflammation in SC
 
Histological features of EAE are inflammation and demy-
elination. The lesions were more extensive in SC than in
brain in our model. Thus, SCs from EAE mice were
stained with hematoxylin and eosin (H&E) and luxol fast
blue (LFB)–cresyl violet to assess the degree of inflamma-
tion and demyelination, respectively. Fig. 3 shows repre-
sentative sections of SC from EAE mice. Severe inflamma-
tion was occasionally associated with tissue vacuolation
Figure 1. PAFR mRNA expression and PAF production in CNS of 
MOG35–55-induced EAE mice. (A) C57BL/6 mice were immunized with 
MOG35–55 peptide and monitored for clinical score up to day 30 (n   10). 
Data represent means   SEM. (B) Expression of PAFR mRNA was quanti-
tated by real-time PCR in SC of naive mice and EAE mice on days 11, 18, 
and 30 (n   6, 5, 5, and 6, respectively). Bars and circles show the mRNA 
levels of PAFR and  -actin, respectively. Dotted line represents a detection 
limit. Data are expressed as means   SEM. *P   0.01 by Mann-Whitney U 
test. (C) PAF level was determined in SC of naive mice and EAE mice on 
days 11, 18, and 30 (n   11, 13, 15, and 14, respectively). Data represent 
means   SEM. *P   0.001, **P   0.01, and ***P   0.05 by analysis of 
variance with Tukey-Kramer test. (D) PAF level in SC was correlated 
positively with the clinical score on days 18 (circle) and 30 (triangle) 
(Spearman rank correlation test: P   0.0001, R   0.85). Each dot 
represents the result of a single animal. 
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(Fig. 3 A), but no vacuolation was observed in naive con-
trols (Fig. 3 B). Inflammatory cells penetrated the pia mater
and infiltrated into the perivascular regions and paren-
chyma; approximately the same number of PMNs was ob-
served in PAFR-WT mice (Fig. 3 C) and PAFR-KO mice
(not depicted) in the acute phase of EAE (153 
 
 
 
 29 and
123 
 
 
 
 30 PMNs/12 sections of SC, respectively, 
 
n
 
 
 
 
 
 4 an-
imals), but not in the chronic phase of EAE. Because nor-
mal myelin of the white matter was highlighted clearly by
LFB–cresyl violet staining, myelin pallor (paler areas in the
white matter) was identified as demyelinated regions. Al-
though margins of myelin pallor were recognized clearly in
the chronic phase of EAE (Fig. 3, F and G), they were ob-
scure in the acute phase (Fig. 3, D and E). Therefore, we
did not evaluate the degree of demyelination in the acute
phase of the disease. Grading of the sections failed to show
a significant
 
 
 
difference in the degree of inflammation be-
tween PAFR-WT and PAFR-KO mice in the acute phase
(Fig. 3 H). Conversely, the degree of inflammation and
demyelination was significantly lower in PAFR-KO mice
than in PAFR-WT mice in the chronic phase of EAE (P 
 
 
 
0.05 and P 
 
 
 
 0.01, respectively) (Fig. 3 I).
Next, we performed immunohistochemistry for the mi-
croglia/macrophage marker Iba1 (Fig. 4, A and B), because
these cells were reported to express a large amount of
PAFR (7). In the acute phase of EAE, infiltration of mono-
cytes/macrophages into inflammatory regions in PAFR-
Figure 2. Changes in clinical score and body weight of MOG35–55-
induced EAE mice. (A and B) PAFR-WT (filled circle) and PAFR-KO (open 
circle) mice were immunized with MOG35–55 peptide and monitored daily 
for clinical score (A) and body weight (B) up to day 42. Data represent 
means   SEM from three independent experiments with a total of 29 
animals in each genotype. (C and D) Mean clinical score (C) and mean body 
weight (D) of only mice with disease onset is shown. Data represent
means   SEM from three independent experiments with a total of 28
and 20 animals for PAFR-WT and PAFR-KO mice, respectively. *P   0.0001 
versus PAFR-WT determined by two-way repeated measures analysis of 
variance.
 
Table I.
 
Clinical parameters of MOG
 
35–55
 
-induced EAE
 
Genotype Incidence
Mean day
of onset
 
a
 
Mean maximal
clinical score
 
a
 
Number of mice 
with
maximal score 
 
 
 
2.5
 
PAFR-WT  28/29 13.6 
 
 
 
 0.4 2.9 
 
 
 
 0.2  25
PAFR-KO  20/29
 
b
 
13.1 
 
 
 
 0.3  2.6 
 
 
 
 0.2
 
c
 
 14
 
b
 
Composite data from three independent experiments are shown.
 
a
 
Mice with score 0 were excluded from the data. Data represent means 
 
 
 
 SEM.
 
b
 
P 
 
 
 
 0.05 by Fisher’s exact test.
 
c
 
P 
 
 
 
 0.05 by Mann-Whitney U test, significantly different from the PAFR-WT group.
Figure 3. Histological analysis of SC. (A–C) H&E staining revealed 
histological features of MOG35–55-induced EAE in PAFR-WT mice. Severe 
inflammation with vacuolation was observed in the anterior and lateral 
funiculi of SC in EAE mice in the acute phase (day 18) of EAE (A), but not in 
naive mice (B). Polymorphonuclear cells infiltrated into SC in the acute 
phase of EAE (C). (D–G) LFB–cresyl violet staining revealed the difference 
in the severity of demyelination between PAFR-WT (D and F) and PAFR-KO 
(E and G) mice in the acute (D and E) and chronic (F and G) phases of EAE. 
Bars, 100  m (A, B); 10  m (C); and 500  m (D–G). (H and I) Histological 
features were scored semi-quantitatively in the acute (n   4) and chronic 
(n   9 or 13) phases as described in Materials and methods. The degrees 
of inflammation (H) and demyelination (I) are shown. Because of unclear 
borders of the areas of myelin pallor, demyelination was not evaluated 
in the acute phase. Each dot represents the histological score of a single 
animal (filled circle, PAFR-WT; open circle, PAFR-KO). The horizontal bars 
designate the mean values of individual groups. *P   0.05 by analysis of 
variance with Dunn’s post hoc test. **P   0.01 by Mann-Whitney U test. 
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KO mice was equivalent to that in PAFR-WT mice (Fig.
4 C). However, in the chronic phase, monocytes/macro-
phage infiltration into CNS of PAFR-KO mice was de-
creased significantly when compared with that of PAFR-
WT mice (P 
 
 
 
 0.05) (Fig. 4 C).
 
PAFR-KO mice had normal immune responses against 
MOG
 
35–55
 
 peptide
 
The immune responses against MOG
 
35–55
 
 peptide were in-
vestigated to understand the mechanisms underlying the
attenuated symptoms of EAE in PAFR-KO mice. Prolifer-
ation assays were performed to quantitate the MOG
 
35–55
 
-
specific proliferative response of T cells generated by im-
munization with MOG
 
35–55
 
 peptide (Fig. 5 A). Among
spleen and LN cells on days 11 and 21, PAFR-KO cells
had tendencies toward more proliferative responses than
did PAFR-WT cells. On day 21, LN cells from PAFR-KO
mice were significantly more responsive to MOG
 
35–55
 
 pep-
tide than were those from PAFR-WT mice (P 
 
 
 
 0.05).
Supernatants from cultured LN and spleen cells on
days 11 (not depicted) and 21 (Fig. 5 B) were collected,
and production of various cytokines (TNF-
 
 
 
; IFN-
 
 
 
;
IL-2, -4, -5, -6, and -10; monocyte chemoattractant pro-
tein (MCP)-1; and IL-12 p70) was determined. Similar
production of IFN-
 
 
 
 and TNF-
 
 
 
, well-known Th1-type
cytokines, were observed in PAFR-WT and PAFR-KO
mice. Intracytoplasmic flow cytometry of MOG
 
35–55
 
-
treated CD4
 
 
 
 T cells also showed the equivalent produc-
tion of IFN-
 
 
 
 in PAFR-WT and PAFR-KO mice (2.7 
 
 
 
0.3% and 3.2 
 
 
 
 0.4%, respectively; Fig. 5 C). As for
Th2-type cytokines, IL-4 and -5 production was less than
the detection limit in almost all specimens. Equivalent
production of IL-6, MCP-1 (Fig. 5 B), and IL-2 and -10
(not depicted) was observed in both genotypes, whereas
IL-12 p70 production was less than the detection limit in
almost all specimens.
Sera collected on day 42 were analyzed for IgG1 and
IgG2a antibodies against the MOG
 
35–55
 
 peptide. PAFR-WT
and PAFR-KO mice produced similar amounts of IgG2a
(Fig. 5 D), a subclass of IgG that is typically associated with a
Th1-type phenotype. IgG1 levels were undetectable under
the experimental conditions.
Expression of mRNA encoding inflammatory mediators 
was reduced in SC of PAFR-KO mice, especially just 
before EAE onset
Gene expression profiles of inflammatory mediators were
examined in SCs removed from PAFR-WT and PAFR-
KO mice on day 8 (before the onset) and day 21 (after the
onset). As shown in Fig. 6 A, about one third of the genes
on the membrane were detected before and after onset.
The ratios of gene expression between PAFR-WT and
PAFR-KO mice before and after onset were calculated to
compare the expression profiles (Fig. 6 B). Before the on-
set, the expression levels of 22 out of 35 detected genes in
Figure 4. Immunohistochemical staining of microglia/macrophages. 
(A) Immunohistochemistry revealed intense infiltration of Iba1-positive 
macrophages just under the pia mater and white matter of SC. (B) Iba1-
positive macrophages invaded parenchyma from the perivascular cuffs 
in the subarachnoidal space. Bars, 20  m. (C) Monocyte/macrophage 
infiltration in the inflammatory area was scored as described in Materials 
and methods (n   4 animals in the acute phase, n   9 or 13 animals in 
the chronic phase). *P   0.05 by Mann-Whitney U test.
Figure 5. Immune responses against MOG35–55 peptide. (A–C) Cells 
from PAFR-WT (black bar) and PAFR-KO (white bar) mice on days 11 and 
21 were stimulated in vitro with MOG35–55 peptide. (A) Proliferative responses 
of LN and spleen cells from EAE mice are shown. *P   0.05 by Student’s t 
test. (B) Supernatants of LN cell culture on day 21 were used to measure 
the concentrations of IFN- , TNF- , MCP-1, and IL-6. Data represent 
means   SEM from four independent experiments (n   12 animals). 
(C) Intracellular staining revealed the population of IFN- –producing CD4  
cells. One mouse representative of three mice is shown. (D) Serum was 
collected 42 d after immunization. Anti-MOG35–55 IgG2a titer was assessed 
by ELISA with a MOG35–55 peptide-coated plate. Each dot represents the 
result of a single animal; the horizontal bars designate the mean values of 
individual groups. There was no significant difference between PAFR-WT 
(closed circle) and PAFR-KO (open circle) mice (n   18 animals).JEM VOL. 202, September 19, 2005 857
ARTICLE
PAFR-WT mice were higher than those in PAFR-KO
mice, such as CC chemokine receptor (CCR)2, CCR5,
CCR7, IL-1RII, IL-2R , IL-6, gp130, eotaxin, and
MCP-5 (Fig. 6 B, left). Higher expression levels of
CCR2 and CCR5 in PAFR-WT mice before the onset
were confirmed by quantitative RT-PCR (Fig. 6 C; 1.9-
fold and 1.6-fold, respectively). After onset, the expres-
sion of 16 out of 35 detected genes was more and 15 out
of 35 detected genes was less in PAFR-WT mice than in
PAFR-KO mice (Fig. 6 B, middle). Fluctuations of the
gene expression after the onset seemed to be smaller than
those before onset. The differences of gene expression be-
fore and after onset in PAFR-WT mice likely reflected
the dynamic changes with disease (Fig. 6 B, right), be-
cause higher expression of CCR2, CCR5, CCR7, and
IL-2R  after onset implied that inflammatory cells vig-
orously infiltrated into CNS with disease development.
Similar tendencies were obtained in PAFR-KO mice
(Table S1, available at http://www.jem.org/cgi/content/
full/jem.20050660/DC1).
PAF affected phagocytic activity in macrophages 
through PAFR
Demyelination is a result of phagocytosis and subsequent local
release of inflammatory mediators by microglia/macrophages.
Because of the high expression of PAFR on these cells, phago-
cytic activity of macrophages was measured in the presence or
absence of PAF. As shown in Fig. 7 A, the uptake of fluores-
cent particles was similar between PAFR-WT and PAFR-KO
cells in the steady-state. Phagocytosis was enhanced approxi-
mately twofold in the presence of PAF in PAFR-WT cells,
whereas there was no effect of PAF on PAFR-KO cells.
TNF-  production also was up-regulated in association with
the enhanced phagocytosis (Fig. 7 B). These results demon-
strated that PAF enhanced phagocytosis and TNF-  produc-
tion through the PAF receptor on macrophages.
DISCUSSION
In this study, we found that PAFR-KO mice, on a C57BL/6
genetic background, showed a lower incidence of MOG35–55-
induced EAE than did PAFR-WT mice (Table I). In ad-
dition, we found that PAFR-KO mice recovered from EAE
symptoms significantly faster and more than did PAFR-
WT mice (P   0.0001), although mice of both genotypes
showed similar symptoms in the acute phase of the disease
(Fig. 2). These results demonstrate the involvement of
PAFR in the induction and chronic phases of EAE. Previ-
ously, several laboratories studied the effects of PAF antago-
nists on EAE with conflicting results (5, 15–17). These dis-
parate effects of PAF antagonists may be due to differences in
antigens, species, and strains, because the pathology of EAE
is known to exhibit large variations depending on these fac-
tors. Furthermore, administration of PAF antagonists always
Figure 6. Effects of PAFR on mRNA expression levels of cytokines, 
chemokines, and their receptors before and after EAE onset. (A) Pooled 
RNA from five SCs of PAFR-WT or PAFR-KO mice was reverse transcribed. 
The resulting cDNA was hybridized to a membrane printed with cDNA 
of inflammation-related genes. (B) The ratios of mRNA expression levels 
in SC of PAFR-WT mice to those of PAFR-KO mice before (left) or after 
(middle) the onset revealed the changes in expression profiles. The ratios 
of mRNA expression levels in SC of PAFR-WT “after the onset” to those 
“before the onset” are also shown (right). Expression levels normalized 
by  -actin and the ratios of gene expression can be found in Table S1. 
(C) The higher mRNA expression of CCR2 and CCR5 in PAFR-WT mice over 
PAFR-KO mice before onset was confirmed by quantitative RT-PCR. Data 
represent means   SEM (n   5 animals).
Figure 7. Effects of PAF on phagocytic activity of macrophages. 
(A) Macrophage phagocytosis of fluorescent particles in the presence or 
absence of PAF was determined by flow cytometry. Data represent
means   SEM (n   3). *P   0.0005 by analysis of variance with Scheffe’s 
test. The results were representative of three independent experiments. (B) 
TNF-  production upon phagocytosis and the effect of mc-PAF, a nonhydro-
lyzable agonist of PAFR, were observed. Data represent means   SEM
(n   3). *P   0.05 by analysis of variance with Scheffe’s test. The results 
were representative of two independent experiments.ROLE OF PLATELET-ACTIVATING FACTOR IN EAE | Kihara et al. 858
would be accompanied by incomplete inhibition and un-
certainty about the specificity of inhibition. However, our
present study using PAFR-KO mice clearly showed the im-
portant role of PAF in the pathogenesis of MOG35–55-induced
EAE, at least for mice with a C57BL/6 background.
In many cases of EAE, differences in the severity of the
disease can be explained by divergence in the immunological
responses to the antigen. Therefore, to address whether the
role of PAFR in EAE was associated with alterations in
the MOG35–55-specific immune responses, we analyzed
the proliferative responses and the Th1/Th2 phenotypes of
MOG35–55-specific T cells from PAFR-KO mice. Prolifera-
tion assays showed no impairment in responsiveness of T
cells to MOG35–55 peptide from PAFR-KO mice (Fig. 5 A).
Rather, the proliferative response of PAFR-KO T cells
tended to be greater than that of PAFR-WT cells. Because
PAF interferes with some processes leading to human CD4 
T cell proliferation (18–20), loss of PAFR signals may en-
hance T cell proliferation slightly. Th1-type responses, such
as production of TNF- , IFN- , and IgG2a, are associated
with pathology of EAE (3, 4). Production of these cytokines
and autoantibody from PAFR-KO mice were comparable to
those from PAFR-WT mice (Fig. 5, B–D). We next mea-
sured other cytokine production in vitro to explain the ame-
lioration of the pathology of PAFR-KO mice, because IL-6
(21–27), -10 (28, 29), and -12 (30–32), and MCP-1 (33)
were reported to play critical roles in EAE. However, the
results did not support a role for PAF in the production of
these cytokines (Fig. 5), which suggested that PAFR-WT
and PAFR-KO mice were immunized equally by MOG35–55
peptide. In addition, PAF was not relevant to Th1-type im-
mune responses during EAE, at least under our experimental
conditions. Although allergy and autoimmunity have long
been regarded as separate immune responses, Steinman and
colleagues (4, 6, 33) proposed that these two pathologies are
joined in EAE on the basis of reports of (a) anaphylaxis to
self-antigens in EAE mice (34); (b) the ability of Th2-type T
cells to induce EAE (35); and (c) the involvement of pros-
taglandin D synthase, histamine receptor type 1, PAFR,
tryptase, and Ig Fc  receptor 1 in EAE (5). Therefore, T
cell–dependent and T cell–independent pathways seem to be
important for understanding the pathology of EAE. Thus, it
is plausible that PAF participates in the pathology of EAE
without affecting direct immune responses through Th1-
type T cells. Other cells that express PAFR, such as mono-
cytes/macrophages, microglia, PMNs, and endothelial cells,
seem to modulate EAE pathology.
It is appropriate for understanding the roles of PAF in
EAE to divide the disease course into induction, acute, and
chronic phases in accordance with the clinical symptoms (Fig.
8). The day on which the clinical symptoms appear in mice is
defined as the onset; the phase before the onset is the induc-
tion phase. Accordingly, the day of onset is the boundary be-
tween the induction and acute phases. In the induction
phase, autoantigen-specific T cells are primed in peripheral
lymphoid organs; subsequently, they expand and differentiate
into Th1-type T cells (36). Then, peripherally activated T
cells (as well as other inflammatory cells) migrate and invade
the CNS (36, 37). Because mice develop clinical symptoms
after these events, T cells are associated tightly with regula-
tion of the onset. Various kinds of KO mice that were im-
paired in Th1-type immune responses showed alterations in
the onset (28, 31, 32, 38). The incidence of EAE in PAFR-
KO mice was significantly lower than that in PAFR-WT
mice (P   0.05), although the mean day of onset was similar
in both genotypes (Table I). Because PAF has little direct ef-
fect on the priming, expansion, and differentiation of T cells,
PAF may control the onset independently of T cells. If
so, how does PAF regulate the onset? Comparison of the
mRNA expression profile in SCs of PAFR-WT and PAFR-
KO mice seems to account for the regulatory role of PAF in
the onset of the disease (Fig. 6 B, left). For example, we ob-
served that IL-6 mRNA expression in SC of PAFR-WT
mice was higher than that of PAFR-KO mice before onset
(Fig. 6 B, left). IL-6 is notable for the important regulation of
the onset of EAE (22, 25). Because spleen and LN cells that
were restimulated with MOG35–55 peptide in vitro produced
comparable amounts of IL-6 in both genotypes (Fig. 5 B),
our results suggest that inflammatory cells other than T cells
are responsible for the local production of IL-6 in SC in
the induction phase. Consistent with a T cell–independent
source of IL-6, IL-6 /  mice that were transferred adoptively
with encephalitogenic T cells from IL-6 /  mice developed
only very mild EAE (22). CCR2 also has been implicated in
EAE development through the T cell–independent pathways
(39, 40). Fife et al. (39) showed that CCR2 /  mice that
were transferred adoptively with MOG35–55-specific CCR2 / 
T cells failed to develop EAE, and had impaired accumula-
tion of macrophages in CNS. They proposed that CCR2 ex-
pression on macrophages was critical for their migration and
accumulation into CNS. The down-regulation of CCR2
mRNA in PAFR-KO mice may be due to reduced infiltra-
tion of macrophages in CNS in the induction phase of EAE
(Fig. 6, B and C). Collectively, in the induction phase of
Figure 8. Possible mechanisms of PAF participation in EAE. BBB, 
blood–brain barrier; ET, endothelial cell; M , macrophage.JEM VOL. 202, September 19, 2005 859
ARTICLE
EAE, PAF seems to regulate disease onset by modulating cy-
tokine production and accumulation of inflammatory cells in
the CNS in a T cell–independent manner.
In the early stage of the acute phase, the clinical course of
PAFR-KO mice was equal to that of PAFR-WT mice until
the peak of EAE. The relative importance of PAF may be re-
duced by the severe inflammatory responses that are evoked
by various other powerful mediators. Rather, the loss of PAF
signaling in inflammatory cells seems to be manifested as time
goes on, because PAFR-KO mice showed a  significantly
lower maximal clinical score than did PAFR-WT mice (P  
0.05) (Fig. 2 C; Table I). However, during the peak in the
acute phase, the expression profile of inflammation-related
genes in PAFR-KO mice was nearly identical to that in
PAFR-WT mice (Fig. 6 B, middle). We also observed the
histologically equivalent infiltration of inflammatory cells, in-
cluding PMNs and macrophages that express a large amount
of PAFR (7, 41), into SCs in PAFR-WT and PAFR-KO
mice (Figs. 3 and 4). The elevated PAF levels at the peak
(Fig. 1 C) conceivably worsened the EAE symptoms by af-
fecting PMNs and macrophages without gene induction.
In the chronic phase of EAE, recovery from the disease
was faster and more significant in PAFR-KO mice than
in PAFR-WT mice (P   0.0001) (Fig. 2). Histologically,
milder inflammation and demyelination were observed in
PAFR-KO mice (Fig. 3), and the number of microglia/
macrophages was reduced in the inflammatory region (Fig.
4). A crucial step in the demyelination process is phagocyto-
sis with subsequent intracellular digestion of myelin by the
infiltrated macrophages (42). We showed that PAFR-WT
and PAFR-KO macrophages showed similar phagocytic ac-
tivity without PAF in vitro, whereas addition of PAF en-
hanced phagocytosis only in PAFR-WT cells (Fig. 7 A).
Our results suggest that reduced inflammation and demye-
lination in PAFR-KO mice are due to the loss of hyper-
phagocytic activity of microglia/macrophages. As a result
of demyelination, myelin debris and apoptotic cells are accu-
mulated in the lesions. Their removal by microglia/mac-
rophages generally serves as repair of the lesions (42–45).
Contrary to this notion, it was reported that macrophage
phagocytosis of myelin induces the production of inflamma-
tory mediators, such as TNF-  (42), which cause inflamma-
tion and oligodendrocyte cell death (46, 47). In fact, TNF- 
production from the macrophages upon phagocytosis was
enhanced significantly by PAF treatment (P   0.05) (Fig. 7
B). In the chronic phase, PAF may prevent remission and
sustain inflammation and demyelination.
Two enzymes are important for the production of PAF
by the remodeling pathway (8): (a) cytosolic phospholipase
A2 (cPLA2), the main supplier of PAF precursor 1-alkyl-sn-
glycero-3-phosphocholine (lyso-PAF) (48); and (b) acetyl
CoA:lyso-PAF acetyltransferase (lyso-PAF AT), which cata-
lyzes transacetylation of the acetyl group from acetyl-CoA to
lyso-PAF. Kalyvas and David (49) showed that cPLA2  is
expressed in CD4  T cells, endothelial cells early in the
course of the disease, and macrophages from mice with se-
vere symptoms. It has been reported that lyso-PAF AT ac-
tivity is present in macrophages (50) and vascular endothelial
cells (51), but not in T cells (52). Because PAFR is expressed
highly on endothelial cells and macrophages, PAF activates
these cells in an autocrine/paracrine manner and most prob-
ably affects the permeability of the blood–brain barrier, ac-
cumulation of inflammatory cells in the CNS, and promo-
tion of inflammation (7, 8, 53, 54). Kalyvas and David (49)
also showed that blocking of cPLA2 by an arachidonic acid
analogue, arachidonyl trifluromethyl ketone, prevented the
onset and progression of EAE. Additionally, Marusic et al.
(55) showed that cPLA2  /  mice developed less severe
EAE than did cPLA2  /  mice after adoptive transfer of en-
cephalitogenic cells from cPLA2  /  mice. WT mice that
were transferred adoptively with cPLA2  /  encephalito-
genic cells developed EAE with a delayed onset and lower
severity compared with those with cPLA2  /  cells. These
results imply that cPLA2  is critical for regulation of the on-
set and progression through the T cell–dependent and -inde-
pendent pathways. Thus, we propose that PAF is a definitive
mediator that regulates onset and progression of EAE in a T
cell–independent manner tightly associated downstream of
cPLA2 . We observed the infiltration of PMNs and mono-
cytes/macrophages into SC in the acute and chronic phases
of EAE (Figs. 3 and 4), when the PAF levels were enhanced
significantly (P   0.001 and P   0.05, respectively) (Fig. 1
C). Because of their cPLA2  and lyso-PAF AT activities (48,
50), it is likely that these cells are responsible for the T cell–
independent PAF production, at least in the acute and
chronic phases.
In conclusion, possible PAF functions in EAE are shown
in Fig. 8. In the induction phase, PAF may be produced lo-
cally in the CNS by endothelial cells and perivascular macro-
phages. The produced PAF enhances the breakdown of the
blood–brain barrier, the migration and accumulation of in-
flammatory cells in the CNS, and the production of proin-
flammatory molecules (including IL-6). In the acute phase,
the effect of PAF may be masked by the severe inflammatory
responses that are elicited by various other powerful media-
tors. However, in the chronic phase, PAF seems to exacer-
bate inflammation and demyelination by releasing a variety
of cytotoxic mediators from phagocytes, such as TNF- ,
leading to a vicious cycle that prevents remission of EAE.
Thus, PAF plays a dual role in EAE pathology through the T
cell–independent pathways in the induction and chronic
phases. Our findings have important implications for the de-
sign of new therapies for MS.
MATERIALS AND METHODS
Mice. PAFR-KO mice were produced on a mixed C57BL/6   129Ola
genetic background as described previously (10). This mutant was back-
crossed onto a C57BL/6 genetic background for 10 generations, and then
PAFR-WT and PAFR-KO mice, derived from the backcrossed PAFR / 
mice, were independently incrossed for the experiments. Female mice were
used at 10–12 wk of age for induction of EAE. The maintenance of the fa-
cility and the use of animals were in full compliance with the University of
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Induction and clinical assessment of EAE. MOG35–55 (MEVGWYR-
SPFSRVVHLYRNGK), corresponding to the fragment of mouse MOG
from 35 to 55, was synthesized by QIAGEN. C57BL/6 WT and PAFR-
KO mice were immunized s.c. in the flank with 300  g of MOG35–55 pep-
tide in 0.1 ml of PBS and 0.1 ml of CFA containing 0.4 mg of Mycobacte-
rium tuberculosis (H37Ra; Difco Laboratories) on days 0 and 7, and were
injected i.p. with 250 ng of pertussis toxin (List Biological Laboratories) on
days 0 and 2. Mice were weighed daily. The clinical signs of EAE were re-
corded daily on a scale of 0 to 5 with 0.5 points for intermediate scores. The
score was defined as follows; 0, no sign; 0.5, mild loss of tail tone; 1.0, com-
plete loss of tail tone; 1.5, mildly impaired righting reflex; 2.0, abnormal
gait and/or impaired righting reflex; 2.5, hind limb paresis; 3.0, hind limb
paralysis; 3.5, hind limb paralysis with hind body paresis; 4.0, hind and fore
limb paralysis; 4.5, moribund; and 5.0, death. The scoring was performed in
a blinded fashion.
Quantification of PAF. SCs of naive mice and EAE mice on days 11,
18, and 30 were removed and frozen immediately with liquid nitrogen until
use. The frozen tissues ( 100 mg) were powdered by an SK-100 mill
(Tokken Inc.), and lipids were extracted with methanol containing deute-
rium-labeled 16:0 PAF (Cayman Chemical) as an internal standard. To re-
move lysophospholipids (mainly lysophosphatidylcholine), which strongly
interfered with the detection of PAF by reversed-phase HPLC-ESI-MS/
MS, the extracted lipid samples were pretreated as described previously (56)
with some modifications. In brief, samples ( 1 ml) were vacuum-evapo-
rated and reconstituted with 50  l of methanol. Then the solutions were
applied to a normal phase HPLC using a silica column (SILICA SG120 S5,
4.6   100 mm; Shiseido) at 40 C with an isocratic mobile phase (dichlo-
romethane/methanol/water/formic acid, 63.3:31.7:5:0.01) at a flow rate of
1.0 ml/min. A TSQ Quantum Ultra triple-stage quadrupole mass spec-
trometer with Ion Max source (Thermo Electron) was used for the online
monitoring of the internal standards and lysophosphatidylcholine. The mass
spectrometry instrument was operated in negative ESI and selected reaction
monitoring mode, whose transitions of 568→59 and 572→59 were used for
the specific detection of PAF and deuterium-labeled PAF, respectively, and
that of 568→508 was used for the nonselective detection of PAF and 18:0
lysophosphatidylcholine. A splitting tee directed  5% of the column efflu-
ent to the ESI source, and the predetermined PAF containing fractions were
collected. After evaporation and reconstitution with 200  l of methanol,
the samples were quantified by reversed-phase HPLC-ESI-MS/MS as de-
scribed previously (57, 58).
T cell proliferation, cytokine production, and intracellular cytokine
staining. Spleens and LNs (axillary and inguinal) from mice were collected
on days 11 and 21 after the first immunization. The organs were dispersed
into a single-cell suspension, and the cells were washed and adjusted to 1.5  
106 cells/ml or 0.75   106 cells/ml in complete RPMI 1640 (containing
10% heat-inactivated FCS, 50  M 2-mercaptoethanol, 2 mM L-glutamine,
1 mM sodium pyruvate, 5% NCTC-109, and penicillin/streptomycin). Cell
suspensions at a volume of 100  l were added to 96-well plates with or
without an equal volume of MOG35–55 at a concentration of 50  g/ml, and
incubated for 72 h at 37 C with 5% CO2. For the last 8 h, 25  l of [3H]thy-
midine (0.5  Ci; GE Healthcare) was added to each well. The cells were
harvested onto UniFilter-GF/C glass filters (PerkinElmer). After the addi-
tion of MicroScint-0 scintillation cocktail (PerkinElmer), radioactivities
were determined using a TopCount microplate scintillation counter (Per-
kinElmer). The stimulation index was defined as a ratio of cpm from culture
with MOG35–55 peptide to that without peptide. For cytokine assays, super-
natants were recovered from cell culture plates and stored at  80 C until
use. The cytokine assay was performed using the cytometric bead array kit
(BD Biosciences). Intracellular staining of cytokines was conducted using
Cytofix/Cytoperm kits (BD Biosciences) following the manufacturer’s rec-
ommendations. FITC-conjugated anti-CD4 antibody (BD Biosciences;
clone GK1.5) and PE-conjugated anti–IFN-  antibody (BD Biosciences;
clone XMG1.2) were used as a cell surface marker and for intracellular cy-
tokine staining, respectively. Isotype antibodies were used in parallel as neg-
ative controls. The cells were analyzed using an EPIX XL flow cytometer
(Beckman Coulter).
Anti-MOG35–55 antibody. MOG35–55 was dissolved at 1  g/ml in car-
bonate buffer (15 mM Na2CO3 and 35 mM NaHCO3, pH 9.5) and was
used to coat 96-well plates at 100  l/well for 3 h at 37 C. The plates were
blocked with 2% BSA in PBS for 1 h at room temperature. Sera were ob-
tained from mice 42 d after sensitization. The diluted serum samples (1:20
or 1:40 in 2% BSA/PBS) were added at 100  l/well and the plates were in-
cubated for 1 h at room temperature and washed three times with 0.05%
Tween-20/PBS. After adding horseradish peroxidase-conjugated anti–
mouse IgG1 or IgG2a antibody (BD Biosciences) (1:1,000 in 2% BSA/
PBS), the plates were incubated for 30 min at room temperature. Substrate
solution (3-ethylbenzthiazoline-6-sulfonic acid dissolved in 0.1 M citric
acid [pH 4.35]) was added and the absorbance at 405 nm was measured
with a plate-reader (Bio-Rad Laboratories).
Histology. On days 18 and 31–32, the mice were anesthetized with ure-
thane and perfused intracardially with 10 ml of ice-cold PBS, followed by 20
ml of 4% paraformaldehyde. SC was fixed overnight in 4% paraformalde-
hyde. From the paraffin-embedded SC, sections of 5- m thickness were
prepared and stained with H&E or LFB-cresyl violet. 11 or 12 transverse
sections from each mouse were observed in a blinded manner to evaluate the
degree of inflammation; 3 transverse sections were observed to evaluate de-
myelination. For evaluation of inflammation, a four-point scale was graded as
follows: 0, no sign or minimal inflammation; 1, inflammatory cell infiltrates
in meninges; 2, perivascular inflammatory cell infiltrates; and 3, marked infil-
tration of inflammatory cells into the parenchyma. For evaluation of demye-
lination, a three-point scale was graded as follows: 0, no sign; 1, crescent-shaped
myelin pallor; and 2, semicircular-shaped myelin pallor. The histological
score represented the mean of the scores of all sections examined.
Immunohistochemistry. Sections were pretreated with 0.3% solution of
H2O2 in methanol containing 0.02% sodium azide to block endogenous
peroxidase activity and with 10% normal goat serum in PBS to block non-
specific binding sites, and were incubated at 4 C overnight with a rabbit
anti-Iba1 antibody (Wako Pure Chemical Industries), which was diluted
1:250 in PBS containing 10% normal goat serum. Sections were incubated
with labeled polymer of the DAKO Envision Plus System (DakoCytoma-
tion) at room temperature for 30 min, following the manufacturer’s recom-
mendations. The reaction was visualized by incubation with 0.2 mg/ml of
3,3 -diaminobenzidine (Wako Pure Chemical Industries) in 0.05 M Tris-
HCl (pH 7.4) containing 3% H2O2 for 5 min. Sections prepared from three
levels of the lumbar SC were examined in individual mice. The number of
monocytes or macrophages in the area of inflammatory cell infiltrates was
graded as one of the four groups according to severity: 0, rare to none; 1,
mild; 2, moderate; and 3, marked. The total scores of three sections were
compared between PAFR-WT and PAFR-KO mice in each region sepa-
rately. The scoring was performed in a blinded fashion.
Gene array screening. On days 8 and 21, SCs were removed from EAE
mice. Because we could not predict which mice developed EAE before the
onset, a pooled sample of total RNA from five mice was used. The mean
clinical scores of PAFR-WT and PAFR-KO at day 21 were 2.4   0.5 and
2.0   0.3 (n   5, means   SEM), respectively. Total RNA was isolated us-
ing Absolutely RNA RT-PCR Miniprep Kit (Stratagene). A pooled RNA
sample from five EAE mice was reverse-transcribed to cDNA and amplified
by linear polymerase replication using the AmpoLabeling-LRP kit (Super-
array Bioscience Corp.) with [ -32P]dCTP (GE Healthcare). The labeled
cDNAs were denatured and hybridized overnight because probes to the
GEArray membrane focused on mouse inflammatory cytokines and recep-
tors (Superarray Bioscience Corp.). The GEArray images were detected us-
ing BAS2000 (Fujifilm), and the radioactivity of each spot was quantified by
MacBAS software (Fujifilm). All signals, obtained by subtracting the lowestJEM VOL. 202, September 19, 2005 861
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measured value from the values of all genes, were normalized to  -actin.
The gene expression profile of PAFR-WT mice was compared with that of
PAFR-KO mice.
Quantitative real-time PCR. Total RNA was extracted from SC as de-
scribed before. The purity and integrity of RNA were determined by the ab-
sorbance at A260/280 and gel electrophoresis, respectively. 1  g of RNA was re-
verse-transcribed by using SuperScript II (Invitrogen) according to the
manufacturer’s instructions. Quantitative PCR for levels of  -actin, CCR2,
CCR5, and PAFR mRNA was performed with LightCycler FastStart DNA
Master SYBR Green I (Roche). Except for PAFR, Primers were designed
across introns to exclude the possibilities of contamination of genomic DNA as
follows: CCR2, forward, 5 -CCTGCAAGACCAGAAGAGG-3 , and reverse,
5 -CAAGGCTCACCATCATCGTA-3 ; CCR5, forward, 5 -TCCTAGC-
CAGAGGAGGTGAG-3 , and reverse, 5 -AGCCGCAATTTGTTTCA-
CAT-3 ; PAFR, forward, 5 -AGCAGAGTTGGGCTACCAGA-3 , and
reverse, 5 -TGCGCATGCTGTAAAACTTC-3 ;  -actin, forward, 5 -GCT-
GTGCTATGTTGCTCTAGA-3 , and reverse, 5 -AATTGAATGTAGTT-
TCATGGATGC-3 . Standard curves for these molecules were generated by
performing 1-, 10-, 100-, 1,000- and 10,000-fold dilutions of murine macro-
phage cDNA samples. The mRNA level for each sample was normalized to
 -actin.
Phagocytosis assay. Phagocytosis assays were performed as described
previously (59). In brief, primary mouse macrophages were harvested from
the peritoneal cavity 3 d after i.p. injection with 2 ml of 4% thioglycollate.
Total cell numbers were determined with a hemocytometer after staining
with Turk solution (Wako). 5   105 cells per well in 24-well plates were
cultured in RPMI 1640 supplemented with 10% FACS at 37 C in 5% CO2.
After incubation for 2 h, the medium was removed and washed with assay
solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2 and 10
mM Hepes [pH 7.4]). Assay solution with 2  m fluorescent particles (Poly-
sciences) was added at the ratio of 20 particles/cell with or without 12.5 nM
1-hexadecyl PAF (Cayman Chemical) and incubated for 30 min at 37 C in
5% CO2. Cells were washed with ice-cold assay solution and gently de-
tached for flow cytometric analysis. For TNF-  detection, the fluorescent
particles, with or without 50 nM 1-hexadecyl 2-methylcalbamoyl PAF
(mc-PAF; Cayman Chemical), were added to 106 cells per well in 24-well
plates. After 30 min of incubation at 37 C, cells were washed twice with
PBS and 300  l of culture medium was added. Supernatants were recov-
ered after 24 h and stored at  80 C until use. TNF-  was measured using
the cytometric bead array kit (BD Biosciences).
Statistical analysis. Results were expressed as means   SEM. As appro-
priate, data were analyzed statistically by means of Student’s t test, Mann-
Whitney U test, Fisher’s exact test, or analysis of variance with Tukey-
Kramer, Dunn’s, or Scheffe’s post hoc test. p-values  0.05 were considered
to be statistically significant.
Online supplemental material. Table S1 shows the expression levels
of inflammation-related genes in the SC together with the ratios of the
gene expression. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050660/DC1.
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